glucose diabetes insulin
Conditions
Interventions
Infusion of placebo or UAG during a euglycemic, hyperinsulinemic clamp.
Sponsors
Erasmus Medical centre
Eligibility
Inclusion criteria
Inclusion criteria: 1. Female or Male subject of 18 years of age or older; 2. Documented diagnosis of type 2 diabetes as defined by American Diabetes Association; 3. Diagnosis of type 2 diabetes for at least 3 months prior to screening; 4. Metformin monotherapy for at least 3 months prior to screening is allowed; 5. Screening HbA1c between 6.5% and 8.5%; 6. Body Mass Index between 25 and 35 kg/m2.
Exclusion criteria
Exclusion criteria: 1. History of or presence of active concomitant conditions or disease that would interfere with the protocol conduct and study assessments, as judged by the investigator; 2. History or presence of long-term type 2 diabetes complications; 3. Clinically significant abnormalities in laboratory evaluation at screening, as judged by the investigator; 4. Use of systemic corticosteroids within 60 days prior to screening; 5. If female, pregnancy or breast feeding; 6. Drug or alcohol dependence or abuse; 7. Participation in a trial of an experimental drug or device within 60 days prior to screening; 30 days for subjects that pariticpated in the oGTT study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insulin levels. | — |
Contacts
Public ContactA.J. Lelij, van der
Postbus 2040
Outcome results
None listed